LEA_2C | R Documentation |
Kaplan-Meier digitized data from LEA, figure 2C (PMID 25691671). A reported sample size of 374 for a primary endpoint of PFS in breast cancer.
LEA_2C
A data frame of 374 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (et, et_b) | |
Martín M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 2015; 33: 1045–52.
summary(LEA_2C)
kmplot(LEA_2C)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.